Rollback, Regulatory Freezes, and Investigations Review

The SEC Staff now allows confidential draft submissions for all follow-on offerings, shelf offerings, and M&A, enhancing flexibility.

By Michele Anderson, Alex Cohen, Paul Dudek, and Joel Trotter

The SEC Staff has expanded the ability of issuers to make confidential submission of draft registration statements and clarified the procedures for making confidential submissions. This new policy takes effect immediately.

The move follows a February 24, 2025, speech by Securities and Exchange Commission Acting Chairman Mark T. Uyeda

The proposed cuts would place a 15% indirect cost rate on all new and existing grant awards received by research institutions and universities.

By Jason B. Caron, Kyle R. Jefcoat, Erin Brown Jones, Elizabeth M. Richards, Dean W. Baxtresser, Jude Volek, Danielle Conley, Anne W. Robinson, and Danielle N. Scheer

Update: On February 21, 2025, the US District Court of Massachusetts ordered that the existing TROs entered on February 10, 2025, be

The administration also turned its focus to copper imports, bird flu, and a proposed new path to American citizenship.

This week, President Trump signed several new executive orders related to healthcare costs, copper imports, and the Department of Government Efficiency (DOGE), among others. The administration also announced strategies for addressing the bird flu breakout as well as a plan for a $5 million “gold card” path to American citizenship. Late last week, a federal judge enjoined implementation of key portions

The Acting SEC Chairman announced regulatory priorities designed to help companies raise capital, widen investment options available to retail investors, and reduce regulatory burdens on smaller public companies.

On February 24, 2025, in a speech to the Florida Bar’s 41st Annual Federal Securities Institute and M&A Conference, Securities and Exchange Commission (SEC or the Commission) Acting Chairman Mark T. Uyeda outlined key SEC priorities aimed at fostering “innovation, job creation, and economic growth” in both the public and private markets.

On February 26, 2025, Latham’s Healthcare & Life Sciences Industry Group discussed the regulatory and legislative considerations under the new Trump administration.

As the healthcare and life sciences industry faces a dynamic landscape, Latham provides valuable insights into the anticipated changes and challenges, with particular focus on key rulemakings and policy pronouncements.

This webcast delves into:

Antitrust

  • How the Trump administration has shifted antitrust enforcement priorities and how to navigate the evolving landscape
    • What to expect from new agency leadership

The Trump administration continues to curb regulation and federal spending while defending previous actions in court.

This week, President Trump issued executive orders asserting direct control over independent agencies and empowering the Department of Government Efficiency (DOGE) to scrutinize agency regulations. Meanwhile, the administration faces a steady stream of lawsuits attempting to block orders cutting off funding and freezing agency activities.

Latham lawyers are carefully monitoring the rollout of President Trump’s policy priorities through executive orders, agency actions, and installment

The order requires “so-called independent regulatory agencies” to align their proposed regulations, legal interpretations, expenditures, and priorities with the White House.

On February 18, 2025, as part of his promise to reform the administrative state, President Trump signed an executive order titled “Ensuring Accountability for All Agencies” (the Order). The Order asserts broad presidential authority to supervise and control all officials within the executive branch, relying on the Constitution’s vesting of executive power in the president as well as the

On February 20, 2025, Latham’s Congressional Investigations lawyers previewed the likely oversight priorities of the new Congress and outlined best practices in responding to congressional investigations.

With the arrival of the 119th Congress and Republican control of the House and Senate, congressional oversight of the private sector will continue to be robust, including on issues such as technology, privacy, healthcare, China, the environment and natural resources, higher education, and climate and DEI initiatives.

This webcast delves into:

  • The mechanics of

On February 20, 2025, Latham’s Congressional Investigations lawyers will preview the likely oversight priorities of the new Congress and outline best practices in responding to congressional investigations.

With the arrival of the 119th Congress and Republican control of the House and Senate, congressional oversight of the private sector will continue to be robust, including on issues such as technology, privacy, healthcare, China, the environment and natural resources, higher education, and climate and DEI initiatives.

During this installment of the firm’s

On February 26, 2025, partners from Latham’s Healthcare & Life Sciences Industry Group will discuss regulatory and legislative considerations under the Trump administration.

The healthcare and life sciences industry faces a dynamic landscape. During this webcast, our partners will provide valuable insights into the anticipated changes and challenges, with a particular focus on key rulemakings and policy pronouncements. We will explore the following areas:

Antitrust

  • How the Trump administration has shifted antitrust enforcement priorities and how to navigate the evolving